These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Quantitative measurements of L-dopa therapy in Parkinson's disease. Webster DD Trans Am Neurol Assoc; 1969; 94():348-50. PubMed ID: 5374483 [No Abstract] [Full Text] [Related]
27. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association]. Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985 [No Abstract] [Full Text] [Related]
28. An analysis of L-dopa-induced dyskinesias in 152 cases of Parkinson's disease. Mones RJ; Elizan TS; Siegel GJ Neurology; 1970 Apr; 20(4):405-6. PubMed ID: 5535050 [No Abstract] [Full Text] [Related]
29. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report. Wycis HT Confin Neurol; 1972; 34(2):130-5. PubMed ID: 4666056 [No Abstract] [Full Text] [Related]
30. Treatment of parkinsonism with levo-dopa: results in 302 cases. Newkirk TA; Magee KR Mich Med; 1971 Sep; 70(22):805-11. PubMed ID: 5141211 [No Abstract] [Full Text] [Related]
31. An evaluation of L-dopa in Parkinson patients. Mones RJ Trans Am Neurol Assoc; 1969; 94():307-9. PubMed ID: 5374472 [No Abstract] [Full Text] [Related]
32. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease. Muenter MD Neurology; 1970 Dec; 20(12):Suppl:6-13. PubMed ID: 4921587 [No Abstract] [Full Text] [Related]
33. Start hesitation--a side effect of long-term levodopa therapy. Ambani LM; Van Woert MH N Engl J Med; 1973 May; 288(21):1113-5. PubMed ID: 4697941 [No Abstract] [Full Text] [Related]
34. [Psychological phenomenona during therapy with L-dopa. I]. Pinto F; Venturini E Riv Neurobiol; 1970; 16(4):406-14. PubMed ID: 5527291 [No Abstract] [Full Text] [Related]
35. A year's experience of L-DOPA in the treatment of Parkinson's disease. Guidetti B; Giuffrè R Acta Neurochir (Wien); 1971; 24(2):81-8. PubMed ID: 5112463 [No Abstract] [Full Text] [Related]
36. [Longtime study on the effects of L-dopa therapy in parkinsonism]. Fischer PA; Schneider E; Jacobi P; Maxion H Nervenarzt; 1973 Mar; 44(3):128-35. PubMed ID: 4572536 [No Abstract] [Full Text] [Related]
37. L-dopa in the treatment of Parkinsonism; a preliminary appraisal. Stellar S; Mandell S; Waltz JM; Cooper IS J Neurosurg; 1970 Mar; 32(3):275-80. PubMed ID: 5416909 [No Abstract] [Full Text] [Related]
38. [Treatment of Parkinson's disease with L-dopa]. Guglielmi L; Vecchi L Clin Ter; 1970 May; 53(3):259-69. PubMed ID: 4917328 [No Abstract] [Full Text] [Related]
39. [Abnormal movements observed during treatment of Parkinson's disease with L-dopa]. Sigwald J; Raymondeaud C Rev Neurol (Paris); 1970 Feb; 122(2):103-12. PubMed ID: 4397165 [No Abstract] [Full Text] [Related]
40. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)]. Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]